Safety and Efficacy of De-escalation Dual Antiplatelet Therapy After BioFreedom™ Stenting in ACS Patients With Moderate-to-high Ischemic and High Bleeding Risk

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 468 participants.

Also called NCT07374718

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 468 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07374718
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07374718. Randomized; no masking; primary purpose treatment. Start 2026-03-01 (anticipated); primary completion 2028-12-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of De-escalation Dual Antiplatelet Therapy After BioFreedom™ Stenting in ACS Patients With Moderate-to-high Ischemic and High Bleeding Risk
Condition
Acute Coronary Syndrome (ACS)
Condition
High Bleeding Risk(HBR)
Intervention (Device)
IVUS-guided BioFreedomTM Drug-Coated Stent Implantation + 1-Month DAPT Followed by 11-Month P2Y12 Inhibitor Monotherapy
Intervention (Device)
Angiography-guided Conventional Drug-Eluting Stent Implantation + 12-Month Dual Antiplatelet Therapy (Aspirin + P2Y12 Inhibitor)
Lead sponsor
Shenyang Northern Hospital (class: other)
Collaborator
Chinese Academy of Medical Sciences, Fuwai Hospital (class: other)

Record details

Record id
cardio:ct-nct07374718
Content hash
a89884a87c42cb3f33d7e88c95bc21376a66b4693c23513da98a0f5ebc4e5bd8